Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Aphylaxis - Overview
Aphylaxis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Aphylaxis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Aphylaxis - Companies Involved in Therapeutics Development
Aquestive Therapeutics Inc
ARS Pharmaceuticals Inc
BioArdis LLC
Bryn Pharma LLC
G2B Pharma Inc
Hoth Therapeutics Inc
JDP Therapeutics Inc
MannKind Corp
Merck & Co Inc
Pharmacin BV
PIMS-E
Shenox Pharmaceuticals LLC
Aphylaxis - Drug Profiles
AQST-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
epinephrine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HLK-0006 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HT-KIT - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JDP-207 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize FcgR1 for Autoimmune Arthritis, Pulmory Inflammation, Systemic Aphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize FcgRIIa for Autoimmune Arthritis, Pulmory Inflammation, Systemic Aphylaxis and Thrombocytopenia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHX-008 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize MRGPRX2 for Aphylaxis, Asthma, Inflammation and Pruritus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XL-499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aphylaxis - Dormant Projects
Aphylaxis - Product Development Milestones
Featured News & Press Releases
Mar 25, 2021: Aquestive Therapeutics provides update on its prodrug candidate AQST-109 at R&D event
Mar 25, 2021: Aquestive Therapeutics provides update on its prodrug candidate AQST-108 at R&D event
Mar 05, 2021: Aquestive Therapeutics to host investor & alyst virtual epinephrine drug delivery R&D event on March 25 at 9:00 a.m. ET
Nov 30, 2020: Recordati: Market authorization application for ARS-1 (epinephrine sal spray) accepted by European Medicines Agency
Oct 29, 2020: Insignis Therapeutics and HLK Pharmacin receive FDA IND clearance to initiate a phase 1 trial with IN-001 for oral aphylaxis treatment
Aug 20, 2020: Aquestive Therapeutics initiates Phase 1 Pharmacokinetic trial of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) in development for treatment of allergic reactions including aphylaxis
Aug 10, 2020: Aquestive Therapeutics receives FDA Fast Track Desigtion for AQST-108 (sublingual film formulation delivering systemic epinephrine) for treatment of allergic reactions including aphylaxis
Jul 13, 2020: ARS Pharmaceuticals announces new patent on ARS-1 (epinephrine sal spray)
Jun 29, 2020: Aquestive Therapeutics files IND for pharmacokinetic clinical trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for aphylaxis treatment
Jun 10, 2020: Bryn Pharma announces the Publication of positive results from its Intrasal Epinephrine Preclinical Study program In three Peer-Reviewed Scientific Jourls
May 04, 2020: Neurelis announces that Intravail Licensee, ARS Pharmaceuticals intrasal epinephrine product, demonstrates bioequivalent exposure to epinephrine injectors
Apr 06, 2020: Bryn Pharma presents data demonstrating comparable pharmacokinetic and pharmacodymic effects of intrasal Epinephrine to intramuscular Epinephrine in adults
Mar 02, 2020: ARS Pharmaceuticals to present new data from Neffy (ARS-1) studies at AAAAI 2020 annual meeting
Feb 06, 2020: Aquestive Therapeutics announces FDA confirmed 505(b)(2) pathway for AQST-108 (sublingual film formulation delivering systemic epinephrine) for aphylaxis treatment
Nov 10, 2019: Bryn Pharma Research on Epinephrine sal Spray Presented at The American College of Allergy, Asthma and Immunology Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development for Anaphylaxis, 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development for Anaphylaxis, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Anaphylaxis - Pipeline by Aquestive Therapeutics Inc, 2021
Anaphylaxis - Pipeline by ARS Pharmaceuticals Inc, 2021
Anaphylaxis - Pipeline by BioArdis LLC, 2021
Anaphylaxis - Pipeline by Bryn Pharma LLC, 2021
Anaphylaxis - Pipeline by G2B Pharma Inc, 2021
Anaphylaxis - Pipeline by Hoth Therapeutics Inc, 2021
Anaphylaxis - Pipeline by JDP Therapeutics Inc, 2021
Anaphylaxis - Pipeline by MannKind Corp, 2021
Anaphylaxis - Pipeline by Merck & Co Inc, 2021
Anaphylaxis - Pipeline by Pharmacin BV, 2021
Anaphylaxis - Pipeline by PIMS-E, 2021
Anaphylaxis - Pipeline by Shenox Pharmaceuticals LLC, 2021
Anaphylaxis - Dormant Projects, 2021